Drug intelligence / Profile preview

GW273225

Development stage: Discontinued
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GW273225 is an investigational small molecule drug developed by GSK for the treatment of epilepsy and bipolar disorder. It was studied as an add-on therapy for partial seizures and evaluated in clinical trials for its safety, tolerability, efficacy, and potential drug interactions—including with oral contraceptives. The development of GW273225 has been discontinued. Its precise mechanism of action is not specified in available sources; however, it was investigated within the context of nervous system diseases[1][3][4][5].

Other names: S,S-hydroxybupropion

Targets

GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on GW273225.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GW273225.

Explore the full profile